Truvestments Capital’s Ascendis Pharma A/S ASND Stock Holding History

Truvestments Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-37	Closed	-$7.36K	–	1049
2025 Q3	$7.36K	Hold	37	–	–	﹤0.01%	758
2025 Q2	$6.39K	Hold	37	–	–	﹤0.01%	705
2025 Q1	$5.77K	Hold	37	–	–	﹤0.01%	740
2024 Q4	$5.09K	Hold	37	–	–	﹤0.01%	698
2024 Q3	$5.52K	Buy	+37	New	+$5K	﹤0.01%	673

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Truvestments Capital's ASND Position: Q4 2025 in Review

Truvestments Capital sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 37 shares — an estimated $7.36K sold.

Truvestments Capital first reported a position in ASND in Q3 2024 and held it in 5 quarters. The position peaked at $7.36K in Q3 2025. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

Truvestments Capital reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
Truvestments Capital sold 37 Ascendis Pharma A/S shares in Q4 2025, an estimated $7.36K.
Truvestments Capital first reported a position in Ascendis Pharma A/S in Q3 2024 and held it in 5 quarters.
Truvestments Capital's Ascendis Pharma A/S position peaked at $7.36K in Q3 2025.
302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Truvestments Capital's 13F filing for Q4 2025, filed 13 Feb 2026.